07/05/2026 Incyte announced long-term data from Phase 3 study of ruxolitinib cream in adult patients with AD Incyte announced long-term data from Phase 3 study of ruxolitinib cream in adult patients with AD (Ref) Incyte announced final 24-week data from its Phase 3, TRuE-AD4 study which evaluated the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical cor